依达拉奉治疗急性脑出血的疗效分析

摘要

目的：探讨依达拉奉对急性脑出血患者血清肿瘤坏死因子α（TNF-α）和白细胞介素-1（IL-1）水平的影响，并观察其治疗效果。方法将首次发病的急性脑出血患者90例，按病例对照研究方法随机分为对照组45例、治疗组45例，对照组是采用常规治疗，治疗组是在常规治疗基础上加用依达拉奉注射液30 mg ＋0．9％氯化钠注射液100 mL 静脉滴注，2次／d，共14 d。比较两组患者于治疗前、后神经功能缺损程度（NIHSS）及日常生活活动量（ADL）评分，并进行疗效评定，检测患者血清 TNF-α、IL-1水平的变化。结果治疗组在治疗后14 d NIHSS 评分[（11．57±1．82）分]及 ADL 评分[（54．84±4．18）分]与对照组[（16．82±2．27）分、（45．13±3．93）分]相比，差异有统计学意义（均 P ＜0．05）；治疗组临床疗效明显优于对照组（P ＜0．05），其神经功能缺损程度明显改善，日常生活能力明显提高。治疗后，治疗组 TNF-α[（13．06±2．90）ng／L]、IL-1[（4．31±2．23）ng／L]水平较对照组[（18．96±3．04）ng／L、（9．76±2．67）ng／L]比较，差异有统计学意义（均 P ＜0．05）。结论依达拉奉能减轻脑出血后炎性反应、清除自由基、改善神经功能缺损。%Objective To explore the influence of edaravone for serum TNF-αand IL-1 and effects of in a-cute intracerebral hemorrhage.Mehtods Ninety cases with acute intracerebral hemorrhage were randomly divided into two groups:45 cases were treated with conventional therapy as control group,45 cases were treated with edaravone 30 mg and 0.9% NS 100 mL iv gtt,bid for 14 days as treatment group.The neurological impairment score (NIHSS)and activi-ty of daily living(ADL)scale were evaluated and compared before and after treatment between two groups.The changes of TNF -αand IL-1 were detected before and after treatment between two groups.Results The NIHSS and ADL of treatment group were higher than those of control group 14 days later(P <0.05).The clinical effect of treatment group was significantly better than control group (P <0.05).Both neurological impairment score and capability of daily living were improved obviously.Serum TNF-αand IL-1 in treatment group were significantly decreased compared with control group after treatment(P <0.05).Conclusion Edaravone can alleviate inflammatory reaction,eliminate free radicals, improve the symptoms of neurological impairment for acute intracerebral hemorrhage.